Bayer Seeks Court Approval for $7.25 Billion Roundup Settlement in Pivotal Hearing

Bayer AG's Monsanto unit is facing a crucial hearing in a Missouri state court on Monday to secure approval for a proposed $7.25 billion settlement aimed at resolving tens of thousands of U.S. lawsuits claiming its Roundup weedkiller causes cancer. The outcome represents a pivotal test of CEO Bill Anderson's strategy to move the company past the costly litigation that has weighed on its performance for years.

The Proposed Settlement

Judge Timothy Boyer is set to examine the settlement framework, which aims to resolve approximately 65,000 current and future claims. The hearing in St. Louis will feature arguments from attorneys on both sides, with some plaintiffs' lawyers contending the deal offers insufficient compensation and unfairly restricts their clients' ability to pursue individual lawsuits. Proponents, however, argue it provides a certain path to compensation for claimants.

According to the proposal announced in February, eligible individuals who developed non-Hodgkin lymphoma after Roundup exposure would receive payouts ranging from $10,000 to $165,000. The specific amount would depend on factors like the severity of the illness and the nature of the exposure. A company spokesman stated that Monsanto believes the settlement "is fair to all parties and warrants final approval."

Context for Investors

The Roundup litigation has been a significant financial overhang for Bayer since its $63 billion acquisition of Monsanto in 2018, depressing its share price and costing billions. This settlement attempt follows a previous $10 billion agreement in 2020 that resolved many existing lawsuits but left the company exposed to future claims. Investors are closely monitoring the proceedings as a key indicator of the management's ability to contain the long-running legal liability.

Ad

A recent Supreme Court ruling in Bayer's favor concerning the adequacy of Roundup's warning label has added a layer of uncertainty for plaintiffs, potentially strengthening the company's negotiating position. Bayer has consistently maintained that Roundup's key ingredient, glyphosate, is safe and does not cause cancer, citing decades of studies.

Conflicting Scientific Assessments

The legal challenges against Roundup gained significant momentum after the World Health Organization’s International Agency for Research on Cancer (IARC) classified glyphosate as a "probable carcinogen" in 2015. However, this finding is contested by other regulatory bodies.

In 2017, the U.S. Environmental Protection Agency (EPA) concluded that glyphosate is not likely to be carcinogenic to humans and does not require a cancer risk warning on product labels. The EPA is currently conducting an updated human health risk assessment for the chemical, which it expects to complete in late 2026.